Trial Profile

A Phase 2, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of JADE101 in Participants With Immunoglobulin A Nephropathy (JUNIPER)

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 02 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JADE 101 (Primary)
Indications IgA nephropathy
Focus Adverse reactions
Acronyms JUNIPER
Sponsors Jade Biosciences

Most Recent Events

23 Apr 2026 Status changed from planning to not yet recruiting.
18 Mar 2026 New trial record
06 Mar 2026 According to Jade Bioscience media release, this trial is expected to begin mid-2026 with preliminary data anticipated in 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com